Clinical Trial Update: The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Engensis (VM202) safety and tolerability in Charcot-Marie-Tooth disease type 1A (CMT1A) has completed and results were posted on 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Charcot-marie-tooth Disease
• Charcot-marie-tooth Disease Type 1a

Drugs mentioned

• Engensis (VM202)

Snippet

Sponsor: Helixmith Co., Ltd. | Conditions: CMT | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-05-29